MicroTransponder is a global medical device company focused on research-based neuroscience solutions to restore sensory and motor function for people with neurological conditions. Its FDA-approved Vivistim Paired VNS System is clinically proven to generate improvement in upper limb function for chronic ischemic stroke survivors after six weeks of in-clinic occupational or physical therapy. Vivistim is an implanted device that a therapist pairs with vagus nerve stimulation (VNS) during high-repetition, goal-oriented therapy tasks to increase neuroplasticity. The company says Vivistim helps stroke survivors regain 2–3 times more upper extremity function. MicroTransponder intends to use the new funds to expand operations and its R&D efforts. The company is headquartered in Austin, Texas. MicroTransponder develops research-based neuroscience solutions and is focused on restoring function for people with neurological conditions that impair sensory and motor function. Its core product is the FDA-approved Vivistim Paired VNS System, which pairs vagus nerve stimulation with rehabilitation therapy to improve upper limb function for stroke survivors. The company says Vivistim generates more improvement in upper limb function than rehabilitation alone after six weeks of in-clinic therapy. MicroTransponder intends to use newly raised funds to support market development and commercialization of Vivistim. Leadership includes CEO Richard Foust and newly appointed COO Prashant Rawat, a named inventor on more than 85 patents and patent applications with over 25 years of medical device experience. Rawat’s role will focus on scaling operations to meet commercial demand, securing additional indications for Vivistim, and advancing development of the next-generation Paired VNS Therapy system. MicroTransponder is a Dallas, Texas-based medical device development company led by CEO Frank McEachern. The company develops and continues to expand neurostimulation programs to treat neurological diseases, including post-stroke motor rehabilitation and tinnitus. Its Vivistim® System is designed to treat stroke patients with upper limb deficit and consists of a small implanted battery and wires that connect to the vagus nerve in the neck. During rehabilitative therapy the device delivers a small amount of neurostimulation to the vagus nerve to strengthen neural pathways in the brain. MicroTransponder closed a $5.5M funding round in October 2015. The company intends to use the funds to commercialize its stroke and tinnitus therapies in Europe in 2016 and to complete additional clinical studies. MicroTransponder, Inc. is a Dallas, TX-based medical device company focused on vagus nerve stimulation therapies and wireless pain platforms. It partners with the University of Texas at Dallas to develop vagus nerve stimulation therapy for various neurological disorders. Initial therapeutic targets are stroke, tinnitus, and chronic pain, and its products include the Vivistim System for post-stroke upper-limb deficits and the Serenity® System for tinnitus. The company is led by CEO Frank McEachern. MicroTransponder intends to use new funding to complete three additional clinical trials for stroke and tinnitus and to continue development of its wireless pain platform. The company completed a $3.39M funding round and previously raised $9.6M in 2010. MicroTransponder is a Dallas, Texas-based medical device company developing a wireless neurostimulation platform for the treatment of chronic pain and other neurological indications. Its initial product is the SAINT™ System for chronic pain. The company announced a $7M Series B financing and was awarded a $2.6M NINDS SBIR FastTrack U44 grant. The grant is a milestone-driven cooperative agreement to support pre-clinical validation of devices for neuropathic pain and manufacturing scale-up. The combined funding has allowed MicroTransponder to hire premier clinical and regulatory expertise and to prepare a series of clinical trials and regulatory filings for the SAINT System. Recent hires include Dr. Evan Rosenfeld as Chief Medical Officer and Vice President of Regulatory Affairs and Brent Tarver as Vice President of Clinical Affairs.

Total raised

$156M

Funding rounds

6

Latest round

Series F

Latest activity

Mar 2025